The approach, called GRAND, uses a second guide RNA to write complementary strands of DNA in targeted genomic locations, resulting in efficient insertions that can be hundreds of base pairs long.

A new method has allowed researchers to conduct the first gene knock-out and knock-in edits on cockroaches and may extend to many other insects.

The results reveal evolutionary relatives of the Cas9 enzyme now used extensively in biotechnology.

The guidance comes after two years of consulting with hundreds of stakeholders, including indigenous peoples, religious leaders, patient groups, and scientists.

A CRISPR-based, paper-strip test developed by Indian researchers performs as well as real-time PCR in identifying the presence of SARS-CoV-2 and returns results within an hour.

Emmanuelle Charpentier and Jennifer Doudna reprogrammed the bacterial immune response into one of the most popular tools for genetics and molecular biology.

Researchers slowed disease progression in the mice by injecting two different viral vectors, each containing one part of the DNA encoding the Cas9 protein, to edit the causative gene.

In demonstrations in cell lines, the technique has a similar efficacy to CRISPR-Cas9, but fewer off-target effects.

Researchers use a CRISPR-Cas9 strategy to expand a desired trait from 50 percent of mouse pups to about 72 percent.

A mouse study details a method called VIVO that predicts the accuracy of any guide RNA.

Researchers have developed a variety of techniques to detect when CRISPR misses the mark.

A tweaked Cas9 nuclease reduces off-target effects to levels below that of previous versions of the enzyme.

In human cells, researchers deploy the genome editor to snip out toxic repetitive sequences.

Scientists correct a mutation in fertilized eggs that causes a severe cardiac disease.

Multiple DNA breaks at either the centromere or the long arm of the mouse Y chromosome cause it to fragment and disappear.

Slight sequence differences confound target sites in precision genome-editing, a study shows.

AcrIIA4, an inhibitor protein from the Listeria bacteriophage, can block DNA from binding to Cas9 during genome editing.

A study of off-target effects that sparked fear among investors of genome-editing companies receives methodological criticisms.

Researchers demonstrate the delivery of AAV-packaged CRISPR-CjCas9 into the muscles and eyes of mice.